Editorial orientation provided by MedAPI — not part of the coding instruction.
C21 covers primary malignant neoplasms arising in the anus and anal canal, including the cloacogenic/transitional zone. Its subsite axis distinguishes the anus (unspecified), anal canal, cloacogenic zone, and an overlapping lesion of the rectum, anus, and anal canal when the site of origin cannot be determined. Anal canal cancers differ clinically and therapeutically from rectal cancers and from malignancies arising in perianal skin.
Common Histologies
- Squamous cell carcinoma, including keratinizing and nonkeratinizing forms, is the predominant histology.
- HPV-associated squamous carcinoma is common; basaloid or cloacogenic terminology may be used for tumors near the anorectal transitional zone.
- Less common tumors include adenocarcinoma and other rare epithelial malignancies.
- Carcinomas arising from the skin of the anus, anal margin, or perianal skin are classified with malignant neoplasms of skin rather than C21. The lesion’s relationship to the dentate line and anal verge, as documented at examination, helps distinguish anal canal tumors from anal margin or skin tumors.
- Malignant melanoma of the anal margin or anal skin is classified separately under the applicable melanoma code.
- Malignant carcinoid and other neuroendocrine tumors of this region are classified in the neuroendocrine neoplasm families rather than C21.
Common Symptoms
- Rectal or anal bleeding (K62.5)
- Anal pain (R52), pressure (R19.8), pruritus (L29.0), or a palpable mass (R22.9)
- Change in bowel habits or stool caliber (R19.4)
- Tenesmus (R15.0), discharge, or fecal incontinence (R15.9)
- Enlarged inguinal lymph nodes (R59.0)
- An incidental lesion found during anorectal examination (K62.89)
Symptoms may be mistaken for hemorrhoids or fissures, so persistent, progressive, or atypical findings warrant direct examination.
Diagnosis
Evaluation commonly includes inspection of the perianal region, digital rectal examination, anoscopy or proctoscopy, and biopsy for histologic confirmation. Examination should document the lesion’s relationship to the anal verge, dentate line, sphincter complex, and rectum because these findings guide selection of the correct C21 subsite versus a skin or rectal code.
Pelvic MRI is often used for local assessment. CT of the chest, abdomen, and pelvis and, in selected cases, FDG PET/CT help evaluate nodal and distant disease. Suspicious inguinal or pelvic lymph nodes may require image-guided sampling.
Staging
Staging uses the applicable TNM system and depends on the tumor’s precise site and histology. For anal canal squamous carcinoma, primary tumor classification is principally based on tumor size and invasion of adjacent organs. Regional nodal assessment includes mesorectal, internal iliac, external iliac, and inguinal nodal basins as defined by the applicable staging system.
Clinical stage influences radiation fields, systemic therapy, prognosis, and the role of salvage surgery.
Molecular Markers
High-risk HPV, particularly HPV 16, is strongly associated with many anal squamous carcinomas. Diffuse p16 expression is commonly used as a surrogate marker of HPV-driven oncogenesis, although p16 and HPV results are not encoded by C21.
PD-L1 expression, mismatch-repair deficiency, microsatellite instability, tumor mutational burden, and other biomarkers may be evaluated in advanced or recurrent disease when relevant to systemic treatment selection. HIV status and other causes of immunosuppression are clinically important but are coded separately.
Common Treatments
Localized anal squamous cell carcinoma is commonly treated with definitive chemoradiation, typically using mitomycin with fluorouracil or capecitabine. Tumor regression can continue for months after treatment, so response assessment is timed accordingly.
Surgery is generally reserved for persistent or locally recurrent squamous carcinoma after chemoradiation and may require abdominoperineal resection. Selected small superficial lesions may be managed with local excision when oncologically appropriate. Anal adenocarcinoma may be treated more like rectal adenocarcinoma, often incorporating surgery, chemotherapy, and radiation according to tumor extent and multidisciplinary assessment.
Recurrent or metastatic disease may be treated with systemic chemotherapy, immunotherapy in appropriate settings, radiation, surgery, or symptom-directed palliative care.
Scope Note
C21 encodes the primary anatomic site as the anus, anal canal, cloacogenic zone, or an inseparable overlapping lesion of the rectum, anus, and anal canal. It does not encode histologic subtype, HPV or other biomarker status, grade, TNM stage, nodal involvement, distant metastatic sites, recurrence, or treatment response. C21 is not used for secondary metastatic involvement of these sites. Carcinomas arising in anal-margin, anal-skin, or perianal skin and melanomas of the anal margin or anal skin are classified in the applicable skin or melanoma families; malignant carcinoid and other neuroendocrine tumors are classified in their designated neoplasm families. The documented relationship to the anal verge and dentate line is therefore essential for distinguishing an anal canal primary from a rectal or skin primary.